Precision In Nanoparticle Processing And Monodispersed Lipid Nanoparticles For Advanced Therapeutics

The biopharmaceutical industry increasingly relies on nanoparticles as vehicles for targeted drug delivery, gene therapy, and vaccine development. Ensuring reproducibility, uniformity, and scalability in nanoparticle production is critical for clinical efficacy and regulatory compliance. DIANT® addresses these challenges with a state-of-the-art platform capable of generating a broad spectrum of nanoparticles with high precision, particularly excelling in producing monodispersed lipid nanoparticles (LNPs), liposomes and polymeric nanocarriers.

An Advanced Platform for Nanoparticle Processing

DIANT’s upstream nanoparticle formation systems enable precise tuning of critical process parameters, such as flow rates, pressures, mixing temperature and degree of mixing. This results in the ability to produce highly uniform nanoparticles with tightly controlled particle size — a critical factor for predictable pharmacokinetics, cellular uptake and immune response modulation. The DIANT® technology goes beyond mixing and the competition by also including single-pass, continuous downstream operations.

The DIANT® sp2TFF/sp3TFF proprietary technology supports downstream single-pass tangential flow filtration. The combination of these upstream and downstream continuous manufacturing systems are designed to deliver unparalleled control over particle size, particle concentration, residual solvent and % encapsulation. Unlike traditional batch or recirculation-based methods that can introduce heterogeneity and reduce yield, DIANT’s approach maintains consistent process conditions and a high degree of control, taking the guesswork out of the process.

Nanoparticles Generated by DIANT’s System

DIANT’s versatile platform supports the generation of several key nanoparticle classes, each optimized for specific therapeutic applications:

1. Lipid Nanoparticles

LNPs have become indispensable in delivering nucleic acids such as mRNA and oligonucleotides. DIANT’s system excels at producing monodispersed LNPs with narrow particle size (typically ~100 d.nm), which is critical for reproducible biodistribution, stability and cellular uptake.

By precisely controlling nucleation and growth during particle formation, the platform minimizes polydispersity and aggregation, resulting in uniform, spherical particles. This monodispersed population of particles directly correlates to higher % encapsulation and predictable in-vivo performance, both of which are essential for RNA-LNP therapeutics and vaccines.

2. Polymeric Nanoparticles

DIANT’s platform can process polymeric nanoparticles composed of biocompatible polymers such as PLGA, PEGylated polymers, and chitosan. The precise flow and mixing controls ensure consistent particle size, surface characteristics and drug loading while enabling controlled release profiles and enhanced therapeutic index.

3. Polymeric Micelles

Polymeric micelles are self-assembled structures that can be formed by amphiphilic block copolymers, ideal for solubilizing lipophilic active pharmaceutical ingredients (APIs). DIANT’s system allows tight control over micelle size and particle stability, producing particles with uniform morphology, high drug loading and reduced aggregation/ worm-like structure formation — all critical for reliable pharmacokinetics and therapeutic efficacy.

4. Polymer/Lipid Hybrid Nanoparticles

Hybrid nanoparticles combine the structural robustness of polymers with the biocompatibility of lipids. DIANT’s technology enables precise polymer-to-lipid ratios and controlled self-assembly, producing particles with tunable mechanical properties, drug release kinetics and targeting capabilities.

5. Nanosuspensions

DIANT’s system can generate nanosuspensions of poorly soluble drugs, producing stable, uniform colloidal dispersions. Narrow particle size distribution may help to improve dissolution rates, bioavailability and formulation stability — crucial parameters for challenging compounds in pharmaceutical development.

The Importance of Polydispersity Index in Nanomedicines

The polydispersity index (PDI), a measure of size uniformity in a sample, is a critical quality attribute for nanoparticle formulations. Polydispersed formulations (e.g. PDI>0.20) can lead to unpredictable drug release, variable biodistribution and unknown immune response. Accordingly, monodispersed formulations (e.g. PDI<0.20), can support longer shelf life and more predictable biological response. DIANT’s systems can support highly monodispersed formulations in LNP and liposome processing through:

  • Precise flow rate and mixing control: Generating a turbulent zone that creates size uniformity.
  • Automated continuous processing: Minimizes batch-to-batch variability and operator error.
  • Optimized nucleation and growth dynamics: Supports formation of uniform, stable nanoparticles from ~10-1000 d.nm.

This level of control is especially valuable for RNA therapeutics, where even small variations in particle size can significantly impact transfection efficiency, protein expression, and immune response.

Advantages of DIANT’s Technology

DIANT’s platform provides tangible benefits for both development and manufacturing:

  • High reproducibility: Consistent particle size and encapsulation across batches.
  • Scalability: Seamless transition from lab-scale research to GMP production without repeating lengthy optimization studies.
  • Enhanced stability: Monodispersed particles reduce aggregation and may extend shelf life.
  • Flexible nanoparticle types: Lipid, polymeric, hybrid and nanosuspension capabilities on a single platform.
  • Regulatory alignment: Following U.S. Food and Drug Administration regulations on 21 CFR Part 11 criteria.

Driving Innovation in RNA and Nanoparticle Therapeutics

As RNA therapeutics, lipid-based vaccines and complex drug delivery systems continue to expand, the demand for reproducible, high-quality nanoparticles is more critical than ever. DIANT® empowers scientists and manufacturers to produce monodispersed, high-quality nanoparticles that meet the stringent requirements of modern medicine.

Whether delivering mRNA vaccines, targeted chemotherapeutics or experimental gene therapies, DIANT’s platform provides the precision, scalability and reliability necessary to accelerate development and achieve predictable, clinically meaningful results.

As nanomedicine shapes the future of healthcare, DIANT® continues to advance cutting-edge solutions in the field.